Michael Koeris is listed as an executive officer and director on 10 SEC Form D filings by 2 issuers between Oct 2013 and Jan 2023: CORVIUM, INC. (Reston, VA — industry reported as "Other" — 2013–2022; $13.5M reported sold to 6 investors) and Xeno Biosciences Inc. (Cambridge, MA — biotechnology — 2018–2023; $9.43M reported sold to 133 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 10 years. Across those companies the filings report $22.9M sold in total.
Listed alongside Timothy Lu (6 shared filings), David Beno (4 shared filings), Guy Broadbent (4 shared filings), Stephen Bloch (4 shared filings), Sam Kass (3 shared filings) and 18 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Michael. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 10 public filings for Michael Koeris and found 11 differences: Form D filed 17 days after the first sale; Form D filed 29 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.